PATRICK GLIHA

Cited source text

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

H.R. 1730

Cancer Drug Parity Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

Original LDA source filings (25)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2019 · second_quarter · Q2

Firm income: —Client expense: $730,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

Source: Senate LDA

Show 96 more cited filings

H.R. 965

CREATES Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

H.R. 965

CREATES Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

H.R. 985

FAST Generics Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

S. 340

A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

S. 340

A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

S. 741

Cancer Drug Parity Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

S. 741

Cancer Drug Parity Act of 2019

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.

H.R. 1

An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

H.R. 1

An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

CREATES Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

CREATES Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

CREATES Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

CREATES Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Protecting Seniors Access to Medicare Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

H.R. 1

An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Cancer Drug Parity Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

FAST Generics Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

Restoring the Patient's Voice Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

CREATES Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Protecting Seniors Access to Medicare Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Protecting Seniors Access to Medicare Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

Protecting Seniors Access to Medicare Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S 1390, "Strong Patents Act", provisions relating to patent reform.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

STRONGER Patents Act of 2017

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Patients' Access to Treatments Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

FAST Generics Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Innovation Act

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Cancer Drug Coverage Parity Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

CREATES Act of 2016

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

S. 632

STRONG Patents Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

S. 632

STRONG Patents Act of 2015

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Cited source text

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Show 21 more original filings

2018 · second_quarter · Q2

Firm income: —Client expense: $670,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

TAX

Taxation/Internal Revenue Code

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

HCR

Health Issues

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2018 · first_quarter · Q1

Firm income: —Client expense: $1,220,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

TAX

Taxation/Internal Revenue Code

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

CPT

2017 · fourth_quarter · Q4

Firm income: —Client expense: $500,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

TAX

Taxation/Internal Revenue Code

H.R. 1, "Tax Cuts and Jobs Act", provisions regarding corporate tax reform.

CPT

2017 · third_quarter · Q3

Firm income: —Client expense: $520,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

HCR

Health Issues

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.

TAX

Taxation/Internal Revenue Code

2017 · second_quarter · Q2

Firm income: —Client expense: $700,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

S 1390, "Strong Patents Act", provisions relating to patent reform.

HCR

Health Issues

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.

TAX

Taxation/Internal Revenue Code

- Corporate Tax Reform including House BluePrint and Border Adjustablity.

2017 · first_quarter · Q1

Firm income: —Client expense: $1,030,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.

TAX

Taxation/Internal Revenue Code

- Corporate Tax Reform including House BluePrint and Border Adjustablity.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2016 · fourth_quarter · Q4

Firm income: —Client expense: $510,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

TAX

Taxation/Internal Revenue Code

Corporate Tax Reform.

HCR

Health Issues

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

2016 · second_quarter · 2A

Firm income: —Client expense: $740,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

TAX

Taxation/Internal Revenue Code

2016 · third_quarter · 3A

Firm income: —Client expense: $820,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

TAX

Taxation/Internal Revenue Code

Corporate Tax Reform.

HCR

Health Issues

2016 · third_quarter · Q3

Firm income: —Client expense: $570,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

HCR

Health Issues

TAX

Taxation/Internal Revenue Code

2016 · second_quarter · Q2

Firm income: —Client expense: $570,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

TAX

Taxation/Internal Revenue Code

Corporate Tax Reform.

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

2016 · first_quarter · Q1

Firm income: —Client expense: $310,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

HCR

Health Issues

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

TAX

Taxation/Internal Revenue Code

Corporate Tax Reform.

2015 · second_quarter · 2A

Firm income: —Client expense: $830,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2015 · fourth_quarter · Q4

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

TAX

Taxation/Internal Revenue Code

Corporate Tax Reform.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2015 · third_quarter · 3A

Firm income: —Client expense: $630,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

HCR

Health Issues

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2015 · second_quarter · Q2

Firm income: —Client expense: $730,000Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

CPT

HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2015 · first_quarter · Q1

Firm income: —Client expense: $480,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)

HCR

Health Issues

H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies

MMM

Medicare/Medicaid

general issues related to patient access

Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

2014 · fourth_quarter · Q4

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

2014 · third_quarter · Q3

Firm income: —Client expense: $498,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

2014 · second_quarter · Q2

Firm income: —Client expense: $450,000Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

implementation of the Affordable Care Act; specialty tier legislation; cost sharing with respect to pharmaceuticals; oral oncology parity

BUD

Budget/Appropriations

implementation of Affordable Care Act

TAX

Taxation/Internal Revenue Code

implementation of the Affordable Care Act

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)